ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CPIX Cumberland Pharmaceutical Inc

1.65
-0.02 (-1.20%)
Last Updated: 14:30:16
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cumberland Pharmaceutical Inc NASDAQ:CPIX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.02 -1.20% 1.65 1.56 1.70 1.65 1.65 1.65 26 14:30:16

Form DEL AM - Delaying amendment

15/12/2023 9:14pm

Edgar (US Regulatory)


cumberlandhead.jpg
December 15, 2023


VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Cumberland Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-276052)

Ladies and Gentlemen:

We are filing this letter in order to provide the staff of the Division of Corporation Finance sufficient time to perform its customary screening and review of registration statements prior to their effectiveness.

Pursuant to Rule 473(c) of the Securities Act of 1933 (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated into the facing page of the Registration Statement on Form S-3 (File No. 333-276052) filed by Cumberland Pharmaceuticals Inc. on December 14, 2023:

“The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.”

If you have any questions or comments in connection with this delaying amendment, please contact Tonya Mitchem Grindon (615-726-5607) of Baker Donelson.


[Signature page follows.]


Very truly yours,


/s/ John Hamm
John Hamm
Chief Financial Officer

CC: Tonya Mitchem Grindon, Baker Donelson


1 Year Cumberland Pharmaceutical Chart

1 Year Cumberland Pharmaceutical Chart

1 Month Cumberland Pharmaceutical Chart

1 Month Cumberland Pharmaceutical Chart

Your Recent History

Delayed Upgrade Clock